World of DTC Marketing

FEBRUARY 22, 2021

billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.

Pharma 181

Pharma Doctors Side effects Prescription 181

European Pharmaceutical Review

FEBRUARY 8, 2023

The number of blood cancer patients receiving CD19-directed CAR-T therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

Marketing 95

Marketing Sales Physicians Patients 95

European Pharmaceutical Review

APRIL 18, 2023

It is estimated that 28 million patients suffer from chronic cough, with 10 million patients globally and six million in the US and European Union (EU) suffering from RCC for over a year, according to a 2015 study. Camlipixant is anticipated to gain regulatory approval and be launched in 2026. per share in cash.

Biopharma 84

Biopharma Sales Patients Medical 84

Pharmaceutical Technology

APRIL 10, 2023

Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. Galvus brand products are mainly used in the treatment of patients with type 2 diabetes.

Manufacturing 52

Manufacturing Medicine Pharma Sales 52

Pharmaceutical Technology

MAY 18, 2023

Non-profit organisations the Max Foundation and the BeiGene Foundation have partnered with global technology company BeiGene to offer access to Brukinsa (zanubrutinib) in 29 low and middle-income countries between 2023 and 2026. This collaboration marks the first time patients with CLL will have access to treatment through Max. “We

Physicians 52

Physicians Patients Medical 52

European Pharmaceutical Review

MARCH 13, 2023

Signing of the MOU “sets up Sandoz to expand patients’ access to the large number of biologics losing patent protection over the next few years,” commented Dominic Wake, Head of Market Access and Corporate Affairs at Sandoz. Full operations is provisionally planned for late 2026.

Networking 81

Networking Competition Pharma Pharmaceutical 81

Pharmaceutical Technology

JULY 26, 2022

This pro forma cash balance of nearly $470m is anticipated to offer a cash runway for the merged company through 2026. An oral, low-dose and once-a-day CETP inhibitor, obicetrapib demonstrated promising safety and >50% LDL-reducing efficacy when given along with high-intensity statins in dyslipidemia patients in a Phase IIb trial.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Competition Marketing Physicians 111

European Pharmaceutical Review

SEPTEMBER 7, 2022

The 2022-2026 workplan of the initiative Accelerating Clinical Trials in the EU ( ACT EU ) has been published by the European Commission (EC), Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA). implementing the CTR – focus on CTIS and CTR training activities and trouble-shooting any issues encountered by trial sponsors.

Medicine 98

Medicine Training Networking Pharmaceutical 98

Pharmaceutical Technology

MARCH 10, 2023

Sandoz CEO Richard Saynor said: “Biosimilar medicines increase access to cutting-edge biologic therapies for the patients who need them most. “At Work on the new biologics production plant is expected to commence this year, and complete operations are scheduled to begin in late 2026.

Food and Drug Administration 52

Food and Drug Administration Networking Medicine Food 52

pharmaphorum

OCTOBER 14, 2022

The project started on 1 October and is scheduled to complete in September 2026. Devices such as smart pill boxes, electronic blood collection devices, wearable monitors, and intelligent labels are increasingly being used to improve healthcare efficiency and conditions for patients, but present an “expanding e-waste challenge.”

Leads 118

Leads Electronics Ethics Healthcare 118

Penrod

APRIL 1, 2024

These policies aim to enhance prior authorization and efficiency for care providers, payers and patients. Payers would be required to expand patient access APIs and implement Provider Access APIs. The CMS estimates the process would save approximately $15 billion in ten years.

Electronics 52

Electronics Insurance Healthcare Healthcare 52

European Pharmaceutical Review

DECEMBER 22, 2022

Upon closing, the ARLA will be extended until 2026. First patient given base-edited CAR T cells. This R&D collaboration includes provision of research funding to Penn with options and licences to certain cell engineering and manufacturing technologies invented/developed in certain Penn laboratories.

Manufacturing 86

Manufacturing Engineering Pharmaceutical Patients 86

pharmaphorum

JUNE 27, 2022

It is also approved for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete surgical removal, and is in phase 3 testing as a combination therapy with rituximab and lenalidomide as a second-line therapy for FL. Ipsen’s CVR offer includes $0.30

Biopharma 91

Biopharma Sales Prescription FDA 91

World of DTC Marketing

OCTOBER 27, 2020

By 2026, national health expenditures will reach $5.7 Technology is increasingly enabling care to be delivered in these more accessible, convenient, lower-cost venues that can both engage people in their own care and drive health care costs down for all payors – especially for the consumer/patient as payor. gross domestic product.

Healthcare 230

Healthcare Healthcare Insurance Retail 230

European Pharmaceutical Review

AUGUST 17, 2022

The WuXi STA Middletown site is located in the Middletown Business Center at 1091 Industrial Drive and facility will create approximately 500 full-time jobs by 2026. WuXi STA has 12 sites across the US, Europe and Asia. The WuXi STA Middletown facility is expected to begin operations in 2025.

Manufacturing 77

Manufacturing Pharmaceutical manufacturing Distribution Pharmaceutical 77

European Pharmaceutical Review

MAY 25, 2023

This award is open to entries from products or services in either the proof of concept or prototype stage with a timeline for launch until the end of 2026. The three award categories for the Health Product Awards 2024 are: Patient-Centric Design Award Eco-Design Award Animal Health.

Distribution 72

Distribution Pharma Pharmaceutical Patients 72

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. starting new lung cancer patients on LIBTAYO® or melanoma patients on Opdualag instead of KEYTRUDA®).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JANUARY 18, 2023

The ROSE2 study found that obicetrapib was able to reduce LDL cholesterol (LDL-c) levels when added to high-intensity statin therapy, raising the prospect that it could help patients struggling to manage their cholesterol levels with current drug therapy. Amgen licensed the rights to NewAmsterdam in 2020.

Pharma 57

Pharma Prospecting Patients Safety 57

pharmaphorum

JANUARY 17, 2023

Preliminary results from a cohort of 101 patients in the study have suggested that they can detect longitudinal change in cognition in Alzheimer’s disease. The company cites market research which predicts that the voice biomarkers market is growing at 66% a year and could reach around $220 million by 2026.

Healthcare 96

Healthcare Healthcare Marketing Patients 96

pharmaphorum

JULY 26, 2022

That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD) who can’t control LDL cholesterol on statin drugs alone.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

NOVEMBER 25, 2022

In early 2026, Grünenthal intends to buy out the remaining stake in the JV to claim full control of the products, which include fentanyl-based products Abstral and PecFent for breakthrough cancer pain, Moventig (naloxegol) for opioid-induced constipation, and nutritional supplement Adcal-D3 for osteoporosis.

Medicine 52

Medicine Marketing Pharma Management 52

Pharmaceutical Technology

OCTOBER 14, 2022

ELVN-001 is a selective small-molecule BCR-ABL inhibitor designed to treat chronic myeloid leukaemia patients. This cash will be used to advance Enliven’s pipeline of candidates through multiple clinical milestones while providing runway into early 2026. Enliven is currently advancing two product candidates, ELVN-001 and ELVN-002.

Management 52

Management Pharmaceutical Healthcare Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Distribution Patients 52

Pharmaceutical Technology

JULY 26, 2022

Although this will provide more efficacious treatment options for NPC patients, an unmet need remains for therapies that prevent the decline in neurological disease, and other musculoskeletal and physiological problems that occur, and significantly improve long-term outcomes.

Marketing 122

Marketing Transportation Leads Patients 122

pharmaphorum

OCTOBER 17, 2022

There are around 31,000 patients with ALS in the US. It remains to be seen whether the data from VALOR will convince the regulator to grant conditional approval while it waits for results from a confirmatory phase 3 trial (ATLAS ) in SOD1-ALS, which is due to generate results in 2026.

FDA 52

FDA Prospecting Competition Safety 52

Pharmaceutical Technology

MAY 9, 2023

The 5th Panel of the Federal Court of the 1st Region (Tribunal Regional Federal da 1ª Região, TRF-1) upheld the existing expiry dates of two patents—one for semaglutide itself (2026), and the other for the delivery mechanism for the oral formulation of the drug, Rybelsus (2031). The average patient lost 15.7%

Marketing 59

Marketing Manufacturing Prospecting Physicians 59

pharmaphorum

AUGUST 5, 2022

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market.

Side effects 83

Side effects Marketing Pharma Medicine 83

Pharmaceutical Technology

MARCH 22, 2023

Mobile health (mHealth) apps can deliver evidence based therapeutic interventions While most mHealth apps are used to collect patient data and track disease progression, in some cases they can belong within digital therapeutics (DTx) by delivering evidence-based therapeutic interventions.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Medical 52

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. Thirdly, digitalisation is aiding efficiency and patient centricity, with healthcare set to become a hybrid of physical and digital in years to come.

Healthcare 87

Healthcare Healthcare Manufacturing Marketing 87

PM360

APRIL 7, 2023

Reduced patient out-of-pocket (OOP) costs in Part D have the potential to reduce beneficiary reliance on foundation support, with commensurate reductions in manufacturer donations required. The business-to-business market leaders must find new and creative ways to help patients receive their treatments.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

JULY 5, 2022

Notable highlights include the central role the UK has played in the field of genomics, with over 500 thousand patients now in the biobank, and the recent RECOVERY trial – the world’s largest clinical trial into treatments for Covid-19, with more than 40,000 participants across 185 trial sites in the UK. Accelerating access for patients.

Patients 93

Patients Medicine Marketing Recruitment 93

pharmaphorum

JANUARY 10, 2023

Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23

Marketing 98

Marketing Pharma Healthcare Healthcare 98

pharmaphorum

SEPTEMBER 23, 2022

In a 9 to 4 vote, the panellists concluded that pan HER2 inhibitor poziotinib should not be approved by the FDA for patients with HER2 exon 20 insertion-mutated, non-small cell lung cancer (NSCLC), despite their pressing need for treatment options.

FDA 52

FDA Patients Marketing Pharma 52

Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% The COVID-19 pandemic seriously accelerated the adoption and implementation of telehealth services, like remote patient monitoring and out-of-office “visits” – a trend that was already on the incline. And what are the implications to patients and providers? over the Forecast Period.”.

Physicians 59

Physicians Safety Patients Marketing 59

Pharmaceutical Technology

AUGUST 12, 2022

This was following a dogged advocacy campaign from ALS clinicians and patients, and the release of additional AMX0035 data. Dr Merit Cudkowicz, a co-principal investigator in Amylyx’s clinical trials, says patients and investigators are pushing for an approval given the unmet need for therapies. “By The FDA’s action plan.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98